GLPwatch

Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report.

J Med Case Rep · 2014

Last updated 2026-09-22

A 38-year-old woman with severe obesity and type 2 diabetes took a GLP-1 receptor agonist (along with metformin and diet changes) for 14 months before planned weight-loss surgery. Her blood sugar control improved (hemoglobin A1c dropped from 7.4% to 5.5%), and she lost 21.2 kg (about 47 pounds) during that time.

AI summary of the abstract below.

JournalJ Med Case Rep, 2014
Citations1
Relative citation ratio0.06
NIH percentile5
Molecules —
Conditions studied Type 2 Diabetes, Obesity

Abstract

INTRODUCTION: Glucagon-like peptide-1 receptor agonists, a new class of anti-diabetic drugs, are widely used in the treatment of type 2 diabetes. However, the effect of glucagon-like peptide-1 receptor agonists on the treatment of preoperative weight loss in obese type 2 diabetic patients has not been reported. CASE PRESENTATION: A 38-year-old Taiwanese woman presented to our hospital with morbid obesity and type 2 diabetes mellitus. Bariatric surgery was recommended by a general surgery specialist. Weight loss before surgery was recommended to reduce the frequency of surgical complications. In addition to diet control with lifestyle modifications, pharmacological treatment with metformin and glucagon-like peptide-1 receptor agonists was administered. Fourteen months of treatment reduced her hemoglobin A1c level from 7.4 to 5.5% and reduced her body weight by 21.2 kg. CONCLUSIONS: One year of diet control with lifestyle modifications and pharmacological treatment with glucagon-like peptide-1 receptor agonists and metformin markedly decreased hemoglobin A1c levels and resulted in effective and substantial weight loss in a morbidly obese patient with dysregulated diabetes during the preoperative period.

Verbatim abstract via PubMed 25213589 ↗